Metformin: Anchor in the Metabolic Journey of Prediabetes Care- Dr Dwaipayan Deb

Prediabetes affects 634.8 million adults globally, i.e., approximately 12% of the adult population (IDF, 2025), with 30.4% prevalence among Indian adults aged ≥45 years. Among pharmacological options, metformin remains the only agent indicated for preventing or delaying T2DM in prediabetes, delivering glycemic, vascular, and vasculo-metabolic hygiene alongside lifestyle intervention in overweight and obese individuals with prediabetes.[1,2,3,4]

Why Does Prediabetes Demand Urgent Clinical Attention?

Prediabetes carries an independent cardiometabolic burden. A meta-analysis of over 10 million individuals found elevated relative risks versus normoglycaemia: 13% for all-cause mortality, 15% for CVD, 16% for coronary heart disease, and 14% for stroke, amplifying to 36% (all-cause mortality) and 37% (cardiovascular disease) respectively, in those with pre-existing ASCVD. A 2026 analysis links prediabetes to 68% higher post-ischemic stroke mortality, and a 2025 meta-analysis of 15 million participants identified a 20% higher hazard for incident atrial fibrillation. AHA 2026 data additionally show young adults with obesity (BMI ≥30 kg/m²) or overweight (≥27 kg/m²) with comorbidities face a 24.8% five-year risk of diabetes progression.[5,6,7,8]

What Makes Metformin the Foundational Anchor in Prediabetes Management?

Metformin is the only pharmacologic agent approved for T2DM prevention in nearly 66 countries, including India (DCGI, 2022). The Expert Group Consensus Statement on Approach and Management of Prediabetes in India frames its value through a triple hygiene framework (Table 1).[2,9]

Table 1: Metformin's Anchoring Role in Prediabetes Management

Anchoring Effect Clinical Rationale Expected Outcome

Glycemic Hygiene Primary prevention of diabetes Delay diabetes onset

Vascular Hygiene Primordial prevention of vascular ill health Prevention of microvascular & macrovascular complications

Vasculo-metabolic Hygiene Secondary prevention of prediabetes Halt metabolic morbidities' risk and progression

What Does the Latest Evidence Say About Early Metformin Use?

● A 2025 meta-analysis of 24 RCTs demonstrated a 25% reduction in T2DM incidence with metformin alone (OR 0.75, p<0.0001), rising to 52% risk reduction when combined with lifestyle interventions versus standard care (OR 0.48, p=0.002). [10]

● The 21-year DPP/DPPOS follow-up (2025) confirms sustained benefit: diabetes developed in 55% of placebo versus 40% of metformin-treated participants (HR 0.83), yielding 2.5 additional diabetes-free years.[11]

● A 2024 meta-analysis further supports metformin's efficacy in prediabetes, significantly reducing diabetes incidence (RR 0.21, p<0.00001), lowering postprandial glucose (MD -2.60, p=0.003), and promoting normoglycemia (RR 2.13, p<0.00001) with a favorable safety profile.[12]

What Are the 2026 Guidelines Recommending for Prediabetes?

Three major 2026 guideline updates converge on metformin's role, each from a distinct clinical vantage point:

• UAE Expert Recommendations (February 2026)- Suggest prediabetes as a reversible early manifestation of CKM syndrome; recommend metformin as the best-studied pharmacotherapy when lifestyle measures are insufficient.[13]

• AACE 2026 Consensus Algorithm (March 2026)-Prioritizes intentional weight loss, with metformin as a pharmacological option to delay T2DM progression.[14]

• ADA Standards of Care 2026-Recommends individualized risk assessment and annual testing; metformin is specifically indicated to prevent hyperglycemia in high-risk clinical scenarios, including patients on PI3Kα inhibitors or high-dose glucocorticoids.[15]

Key Takeaways

✔ Prediabetes affects 634.8 million adults globally and 30.4% of Indian adults aged ≥45 years, with substantially elevated risks of diabetes progression, CVD, stroke, and atrial fibrillation extending well beyond glycemic disease.[1,5,6,7,8]

✔ Metformin is the only pharmacological agent approved for T2DM prevention in 66 countries, reducing diabetes risk by up to 52% with lifestyle co-intervention and extending diabetes-free survival.[9,10,11]

✔ The 2026 UAE, AACE, and ADA guidance updates collectively reinforce metformin as the essential therapeutic anchor across the gluco-metabolic care continuum in prediabetes.[13,14,15]

Abbreviations

T2DM: type 2 diabetes mellitus; IDF: International Diabetes Federation; ASCVD: atherosclerotic cardiovascular disease; BMI: body mass index; DCGI: Drug Controller General of India; CVD: cardiovascular disease; RCT: randomized controlled trial; OR: odds ratio; HR: hazard ratio; RR: relative risk; MD: mean difference; DPP/DPPOS: Diabetes Prevention Program/Diabetes Prevention Program Outcome Study; CKM: cardiovascular-kidney-metabolic; UAE: United Arab Emirates; AACE: American Association of Clinical Endocrinology; ADA: American Diabetes Association; GLP-1 RA: glucagon-like peptide-1 receptor agonist; PI3Kα: phosphatidylinositol 3-kinase alpha